Floatz logo

Galantamine Hydrobromide

Vascular Dementia

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.UNKNOWNPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Vascular Dementia cohort.

Asset / SponsorPhaseRating
Pittsburgh Compound B Unlabelled
National Taiwan University Hospital
Phase 4BB
Risperidone
Janssen-Cilag Pty Ltd
Phase 3BB
Cilostazol
Peking University First Hospital
Phase 4BB
Aspirin
Peking University First Hospital
Phase 4BB
Oxycodone Hydrochloride, Hydrocodone-
VA Office of Research and Development
Phase 4BB

View all 40 →

Same molecule, other indications

Galantamine Hydrobromide is also rated in:

Alzheimer diseaseDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
dementiaDormant
BB
Indicative · Phase 3
70 / 100
View asset →
mental disorderDormant
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →